Latest News
Starbucks reports second-quarter revenue of $8.76 billion, missing analyst estimates of $8.86 billion, according to Benzinga Pro.
Via Benzinga · April 29, 2025
On another set of horrid trade data, the GDPNow forecast ends on a low note.
Via Talk Markets · April 29, 2025
Recreational vehicle (RV) and boat retailer Camping World (NYSE:CWH) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3.6% year on year to $1.41 billion. Its non-GAAP loss of $0.16 per share was 21.6% above analysts’ consensus estimates.
Via StockStory · April 29, 2025
Business software provider Freshworks (NASDAQ: FRSH) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 18.9% year on year to $196.3 million. Guidance for next quarter’s revenue was better than expected at $198.8 million at the midpoint, 0.6% above analysts’ estimates. Its non-GAAP profit of $0.18 per share was 39.4% above analysts’ consensus estimates.
Via StockStory · April 29, 2025
Via Benzinga · April 29, 2025
Via Benzinga · April 29, 2025
Crockett initiates coverage of TTD with Buy rating and $77 price target. Despite macro concerns and competition, TTD is well-positioned in AdTech's growth, driven by CTV and programmatic. Stock has dropped due to Q4 miss but consensus estimates for growth remain positive. TTD is a leading DSP with a history of strong growth. Crockett projects Q1 revenue of $578.7 million and EPS of $0.25. TTD stock currently at $54.61.
Via Benzinga · April 29, 2025
Currently trading at approximately $61 per barrel, WTI has decreased by about 13.76% since the beginning of the year.
Via Talk Markets · April 29, 2025
Social network Snapchat (NYSE: SNAP) announced better-than-expected revenue in Q1 CY2025, with sales up 14.1% year on year to $1.36 billion. Its GAAP loss of $0.08 per share was 40.3% above analysts’ consensus estimates.
Via StockStory · April 29, 2025
Wall Street sees Q2 EPS 48c, revenue $8.83B.
Via Talk Markets · April 29, 2025
Visa releases its second-quarter results after Tuesday's closing bell. Here's a look at the details from the report.
Via Benzinga · April 29, 2025
Coffeehouse chain Starbucks (NASDAQ:SBUX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 2.3% year on year to $8.76 billion. Its GAAP profit of $0.34 per share was 29.2% below analysts’ consensus estimates.
Via StockStory · April 29, 2025
Logitech reported better-than-expected earnings for its fiscal fourth quarter but sales were weaker than views. Logitech stock fell.
Via Investor's Business Daily · April 29, 2025
Power conversion and control solutions provider Vicor Corporation (NASDAQ:VICR) missed Wall Street’s revenue expectations in Q1 CY2025, but sales rose 12% year on year to $93.97 million. Its GAAP profit of $0.06 per share was 69.2% below analysts’ consensus estimates.
Via StockStory · April 29, 2025
Booking stock slipped late Tuesday despite the travel booking company reporting first quarter earnings and sales that exceeded expectations.
Via Investor's Business Daily · April 29, 2025
Cybersecurity software maker Tenable (NASDAQ:TENB) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 10.7% year on year to $239.1 million. Guidance for next quarter’s revenue was better than expected at $242 million at the midpoint, 0.6% above analysts’ estimates. Its non-GAAP profit of $0.36 per share was 27.5% above analysts’ consensus estimates.
Via StockStory · April 29, 2025
Packaged snacks company Mondelez (NASDAQ:MDLZ) met Wall Street’s revenue expectations in Q1 CY2025, but sales were flat year on year at $9.31 billion. Its non-GAAP profit of $0.74 per share was 12.2% above analysts’ consensus estimates.
Via StockStory · April 29, 2025
Sysco Corp reported Q3 FY25 sales of $19.60B, missing analyst estimate of $20.05B. Adverse weather and consumer confidence contributed to lower results.
Via Benzinga · April 29, 2025
Decision Day Deferred: SEC Pushes XRP ETF to June 17 and Dogecoin ETF to June 15.
Via Talk Markets · April 29, 2025
Via Benzinga · April 29, 2025
Analysts are lowering their price targets on Meta Platforms ahead of Q1 results. Will the company report a weak report and guidance?
Via Benzinga · April 29, 2025
Rosenblatt analyst initiates coverage on Magnite Inc. with a Buy rating and $18 price forecast. Potential growth if regulatory actions level the field with Google.
Via Benzinga · April 29, 2025
Hotel and casino entertainment company Caesars Entertainment (NASDAQ:CZR) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 1.9% year on year to $2.79 billion. Its GAAP loss of $0.54 per share was significantly below analysts’ consensus estimates.
Via StockStory · April 29, 2025
Communications chips maker Qorvo (NASDAQ: QRVO) reported Q1 CY2025 results topping the market’s revenue expectations, but sales fell by 7.6% year on year to $869.5 million. Guidance for next quarter’s revenue was optimistic at $775 million at the midpoint, 2.4% above analysts’ estimates. Its non-GAAP profit of $1.42 per share was 41.6% above analysts’ consensus estimates.
Via StockStory · April 29, 2025
Machinery provider H&E (NASDAQ:HEES) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 14% year on year to $319.5 million. Its non-GAAP profit of $0.03 per share was 95.5% below analysts’ consensus estimates.
Via StockStory · April 29, 2025
TSMC is manufacturing in the U.S. because of Trump's tariffs, Lutnick insists, even though the company benefitted from Biden-era planning.
Via Benzinga · April 29, 2025
Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Tuesday and discover the stocks that are dominating the trading activity and setting the pace for the market.
Via Chartmill · April 29, 2025
While Carnival struggled under a rough consumer environment, a rival's positive earnings results could help spark a recovery for CCL stock.
Via Benzinga · April 29, 2025
Iridium stock is exposed to higher tariffs under the Trump administration.
Via Talk Markets · April 29, 2025
Via Benzinga · April 29, 2025
The company sells a rival to Pfizer' heart treatment, Vyndaqel. Sales smashed expectations in its first quarter on the market.
Via Investor's Business Daily · April 29, 2025
Via Benzinga · April 29, 2025
Via Benzinga · April 29, 2025
Via Benzinga · April 29, 2025
Via Benzinga · April 29, 2025
Via Benzinga · April 29, 2025
Via Benzinga · April 29, 2025
Via Benzinga · April 29, 2025